Baird lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Fate Therapeutics price target lowered to $2 from $10 at Barclays
- Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
- Fate Therapeutics reports Q1 EPS (32c), consensus (38c)
- FATE Upcoming Earnings Report: What to Expect?
- Fate Therapeutics receives RMAT designation from FDA for FT819